Abstract: It has been discovered that certain genetic variants correlate with risk of urinary bladder cancer in humans. The invention relates to use of such variants in methods of disease management of urinary bladder cancer, including various diagnostic methods.
Abstract: The present invention discloses certain genetic variants as susceptibility variants for peripheral arterial disease (PAD) and abdominal aortic aneurysm (AAA). The invention relates to risk management using such variants. The invention further relates to kits for use in risk assessment of PAD and AAA.
Type:
Application
Filed:
April 1, 2009
Publication date:
October 27, 2011
Applicant:
deCODE Genetics ehf.
Inventors:
Thorgeir Thorgeirsson, Patrick Sulem, Frank Geller, Kristinn P. Magnusson
Abstract: The invention discloses genetic variants that have been determined to be susceptibility variants of thyroid cancer. Methods of disease management, including determining increased susceptibility to thyroid cancer, methods of predicting response to therapy and methods of predicting prognosis of thyroid cancer using such variants are described. The invention further relates to kits useful in the methods of the invention.
Type:
Application
Filed:
August 12, 2009
Publication date:
September 22, 2011
Applicant:
deCODE Genetics ehf.
Inventors:
Julius Gudmundsson, Daniel Gudbjartsson, Patrick Sulem
Abstract: The invention discloses genetic variants that have been determined to be susceptibility variants of cancer. Methods of disease management, including determining increased susceptibility to cancer, methods of predicting response to therapy and methods of predicting prognosis of cancer using such variants are described. The invention further relates to kits useful in the methods of the invention.
Type:
Application
Filed:
August 17, 2009
Publication date:
September 1, 2011
Applicant:
deCODE Genetics ehf.
Inventors:
Thorunn Rafnar, Patrick Sulem, Simon Stacey
Abstract: The present invention relates to a chemical genus of 3-(triaryl)-2-aminopropanol derivative inhibitors of LTA4H (leukotriene A4 hydrolase) useful for the treatment and prevention of inflammatory diseases and disorders.
Type:
Grant
Filed:
August 3, 2007
Date of Patent:
August 2, 2011
Assignee:
Decode Genetics EHF
Inventors:
Vincent Sandanayaka, Jasbir Singh, David Sullins, Mark E. Gurney
Abstract: The invention pertains to certain genetic variants on Chr2q14, Chr2q35 and Chr16q12 as susceptibility variants of breast cancer. Methods of risk assessment and diagnosis of increased and/or decreased susceptibility to breast cancer, using such variants are described. The invention further relates to kits for diagnosing a susceptibility to breast cancer.
Type:
Application
Filed:
March 26, 2008
Publication date:
May 19, 2011
Applicant:
deCODE Genetics ehf
Inventors:
Simon Stacey, Patrick Sulem, Andrei Manolescu
Abstract: The present invention discloses certain genetic variants as susceptibility variants for lung cancer. The invention relates to methods of risk assessment using such variants. The invention further relates to kits for use in risk assessment of lung cancer.
Type:
Application
Filed:
February 16, 2009
Publication date:
April 21, 2011
Applicant:
deCODE Genetics ehf.
Inventors:
Thorunn Rafnar, Thorgeir E. Thorgeirsson, Patrick Sulem, Frank Geller
Abstract: It has been discovered that certain genetic markers are associated with risk of prostate cancer. The invention describes diagnostic applications for determining a susceptibilty to prostate cancer using such markers, including methods, uses, kits, and computer applications.
Abstract: The invention pertains to certain genetic variants on Chr5p12 and Chr10q26 as susceptibility variants of breast cancer. Methods of disease management, including diagnosing increased and/or decreased susceptibility to breast cancer, methods of predicting response to therapy and methods of predicting prognosis using such variants are described. The invention further relates to kits useful in the methods of the invention.
Type:
Application
Filed:
May 21, 2008
Publication date:
January 20, 2011
Applicant:
deCODE Genetics ehf.
Inventors:
Simon Stacey, Patrick Sulem, Andrei Manolescu
Abstract: Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described.
Type:
Grant
Filed:
April 22, 2004
Date of Patent:
December 14, 2010
Assignee:
deCODE Genetics ehf.
Inventors:
Anna Helgadottir, Mark Gurney, Jeffrey R. Gulcher, Hákon Hákonarson
Abstract: Polymorphisms in the FLAP and LTA4H gene are shown by genetic association analysis to be susceptibility markers for myocardial infarction (MI) and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides methods of prophylaxis therapy for MI in human subjects having a race including black African ancestry by administering to the subject a composition comprising a therapeutically effective amount of MI therapeutic agent that inhibits leukotriene synthesis in vivo. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a statin and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD.
Type:
Application
Filed:
March 30, 2006
Publication date:
August 26, 2010
Applicant:
deCODE Genetics ehf.
Inventors:
Anna Helgadottir, Hákon Hákonarson, Jeffrey R. Gulcher, Mark E. Gurney
Abstract: The present invention relates to a chemical genus of biaryl nitrogen-attached heterocycles that are inhibitors of LTA4H (leukotriene A4 hydrolase). The compounds have the general formula They are useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.
Type:
Grant
Filed:
August 3, 2006
Date of Patent:
July 6, 2010
Assignee:
deCODE genetics ehf
Inventors:
Vincent Sandanayaka, Jasbir Singh, Li-Ming Zhou, Mark E. Gurney
Abstract: Polymorphic variants (e.g., certain alleles of polymorphic markers) that have been found to be associated with high blood eosinophil counts, conditions causative of eosinophilia (e.g., asthma, myocardial infarction), and/or hypertension are provided herein. Such polymorphic markers are useful for diagnostic purposes, such as in methods of determining a susceptibility, and for prognostic purposes, including methods of predicting prognosis and methods of assessing an individual for probability of a response to a therapeutic agent, as further described herein. Further applications utilize the polymorphic markers of the invention include, screening methods and genotyping methods. The invention furthermore provides related kits, computer-readable medium, and apparatus.
Type:
Application
Filed:
December 11, 2009
Publication date:
June 24, 2010
Applicant:
deCODE Genetics ehf.
Inventors:
Daniel Gudbjartsson, Unnur S. Bjornsdottir, Patrick Sulem
Abstract: A chemical genus of biphenyl heterocycle derivative inhibitors of LTA4H (leukotriene A4 hydrolase) of the formula: is disclosed. In these compounds Q and Z are (CH2)1-10; in which one or two (CH2) may optionally be replaced by —O—, —NR1—, —SO—, —S(O)2—, —C(?O)— or —C?O(NH)—; Het is a 5-7 membered non-aromatic nitrogen heterocycle; and W is acyl, hydroxyl, carboxyl, amino, carboxamido, aminoacyl, —COOalkyl, —CHO, heterocyclyl, substituted aryl, or substituted heterocyclyl, or taken together ZW can be H or —COOalkyl. The compounds are useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.
Type:
Grant
Filed:
August 2, 2007
Date of Patent:
June 1, 2010
Assignee:
deCODE genetics ehf
Inventors:
Vincent Sandanayaka, Pushpa Chandrasekar, Mark E. Gurney
Abstract: A region on chromosome 8q24.21 has been demonstrated to play a major role in particular forms of cancer. It has been discovered that certain markers and haplotypes are indicative of a susceptibility to particular cancers, including prostate cancer. Diagnostic applications for identifying a susceptibility to cancer using these markers and haplotypes are described.
Abstract: The invention relates to methods of risk assessment and diagnosis of susceptibility to coronary artery disease and myocardial infarction, by assessing the presence or absence of alleles of certain polymorphic markers found to be associated with coronary artery disease and myocardial infarction. The invention also relates to methods for use of such polymorphic markers for predicting drug response to drugs for treating cardiovascular disease, or for monitoring the effectiveness of such drugs. The invention further relates to kits encompassing reagents for use in these methods.
Abstract: Peri-substituted, fused bicyclic ring carboxylic acids useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed.
Type:
Grant
Filed:
October 11, 2005
Date of Patent:
May 11, 2010
Assignee:
Decode Genetics, EHF
Inventors:
Jasbir Singh, Mark Gurney, Georgeta Hategan, Peng Yu, David Zembower, Nian Zhou, Alexandre Mikhaylovich Polozov, Wayne Edward Zeller
Abstract: The invention relates to methods of diagnosing susceptibility to cardiovascular disease, including coronary artery disease. MI, abdominal aorta aneurysm, intracranial aneurysm restenosis and peripheral arterial disease, by assessing the presence or absence of alleles of certain polymorphic markers found to be associates with cardiovascular disease. The invention further relates to kits encompassing reagents for assessing such markers, and methods for assessing the probability of response to therapeutic agents and methods using such markers.
Type:
Application
Filed:
February 21, 2008
Publication date:
March 18, 2010
Applicant:
deCode Genetics ehf
Inventors:
Anna Helgadottir, Gudmar Thorleifsson, Andrei Manolescu
Abstract: The present invention relates to a chemical genus of biaryl nitrogen-attached heterocycles that are inhibitors of LTA4H (leukotriene A4 hydrolase). The compounds have the general formula: They are useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.
Type:
Grant
Filed:
August 3, 2006
Date of Patent:
March 9, 2010
Assignee:
deCODE genetics, ehf
Inventors:
Vincent Sandanayaka, Jasbir Singh, Lei Zhao, Mark E. Gurney
Abstract: The present inventions discloses genetic markers and haplotypes that have been found to be associated with risk of Restless Legs Syndrome (RLS), Periodic Limb Movement Disorder (PLMD), and Periodic Limb Movements of Sleep (PLMS). Methods for determination of susceptibility of these disorders are disclosed using such markers, as are kits useful in such determination.